t.zielinski96/100
Residual-solvent screen included unrequested. Identity confirmed by two orthogonal methods.
GGPeps — Nantong Guangyuan Chemical Co., Ltd.
Nantong, CN. The index holds 371 assay reports across 65 batches and 28 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where GGPeps sells
Nantong Guangyuan Chemical Co., Ltd. sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- Nantong Guangyuan Chemical Co., Ltd.
- Short code in this index
- GGPeps
- Also known as
- GGPeps · GYC · GYC Peptides · Guangyuan Chemical
- Domain
- ggpeps.net →
- City
- Nantong
- Region
- Jiangsu
- Country
- CN
- Established
- not stated
- First record in index
- 26 Apr 2024
- Most recent record
- 25 Sep 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.6%
n=371
Retail, shipped to the buyer
71.7%
n=371
Direct to the laboratory
9.7%
n=371
Median courier leg, direct despatch
6d
n=36
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 54 | 14.6% |
| Retail purchase, shipped to the buyer | 213 | 57.4% |
| Retail purchase via a third-party forwarder | 53 | 14.3% |
| Supplier despatch direct to the laboratory | 36 | 9.7% |
| Laboratory retained-sample archive | 15 | 4.0% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 371 GGPeps records the index holds, 54 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 19 of the 28 compounds GGPeps is represented by here — BPC-157, Retatrutide, Tirzepatide, Enclomiphene citrate, Liraglutide, Semaglutide and 13 further compounds. Those are the GGPeps lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
No contributor to this index has named a regional stock location for GGPeps. 54 of its records nevertheless arrived by a domestic-warehouse route, so stock is held somewhere; the index does not know where and will not guess.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is GGPeps's own reviewers: 4 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where GGPeps despatched a sample direct to a laboratory, the courier leg ran a median 6 days across 36 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.76%
n=371
Interquartile range
0.91pp
n=371
10th percentile
97.98%
n=371
Pass rate vs index spec
93.8%
n=371
Median recovery vs claim
97.7%
n=209
Median water
4.59%
n=371
Median |mass error|
2.4ppm
n=310
Records carrying a flag
21.0%
n=371
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.79pp
n=47
Index median spread
0.67pp
n=28
Lots tested 3+ times
47
n=65
Across the 47 GGPeps lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.79 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.08pp
n=65
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
62%
n=65
Divergences beyond 1 pp
0%
n=65
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.72%
n=320
Supplier-supplied median
99.22%
n=36
Supplier-supplied share of records
9.7%
n=371
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of GGPeps batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
77/100
n=65
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 78% | 25 points | |
| Peptide content stated | 66% | 20 points | |
| Endotoxin stated | 26% | 15 points | |
| Named impurities rather than a total | 40% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Retatrutide | Incretin | 56 | 98.44 | 98.37 | +0.07 | 96.5 | 100 |
| BPC-157 | Tissue-repair | 56 | 98.82 | 99.16 | -0.34 | 98.0 | 100 |
| Tirzepatide | Incretin | 36 | 98.46 | 98.55 | -0.09 | 97.0 | 100 |
| Semax | Neuroactive | 23 | 99.38 | 99.46 | -0.08 | 98.5 | 100 |
| Semaglutide | Incretin | 23 | 98.46 | 98.89 | -0.43 | 97.0 | 100 |
| Liraglutide | Incretin | 19 | 98.77 | 99.00 | -0.23 | 97.5 | 100 |
| Enclomiphene citrate | Non-peptide | 16 | 98.32 | 99.44 | -1.12 | 98.5 | 31 |
| CJC-1295 (no DAC) | Growth-hormone | 15 | 98.27 | 99.09 | -0.82 | 98.0 | 87 |
| Survodutide | Incretin | 14 | 97.66 | 98.38 | -0.72 | 96.5 | 100 |
| TB-500 | Tissue-repair | 14 | 99.58 | 99.53 | +0.05 | 98.5 | 100 |
| NAD+ | Non-peptide | 12 | 98.16 | 99.28 | -1.11 | 97.0 | 100 |
| Ipamorelin | Growth-hormone | 10 | 99.20 | 99.47 | -0.27 | 99.0 | 80 |
| GHRP-2 | Growth-hormone | 10 | 99.15 | 99.28 | -0.14 | 99.0 | 80 |
| Selank | Neuroactive | 9 | 99.62 | 99.59 | +0.03 | 99.0 | 78 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 9 | 99.81 | 99.49 | +0.32 | 98.5 | 100 |
| Melanotan II | Melanocortin-receptor | 8 | 99.22 | 99.42 | -0.20 | 98.5 | 100 |
| Sermorelin | Growth-hormone | 8 | 98.53 | 99.06 | -0.52 | 98.0 | 100 |
| IGF-1 LR3 | Growth-hormone | 5 n=5 | 98.11 | 98.28 | -0.17 | 95.0 | 100 |
| Hexarelin | Growth-hormone | 5 n=5 | 99.28 | 99.59 | -0.31 | 99.0 | 80 |
| SLU-PP-332 | Non-peptide | 4 n=4 | 98.93 | 98.88 | +0.06 | 98.0 | 100 |
| MGF | Growth-hormone | 4 n=4 | 98.48 | 99.29 | -0.81 | 97.5 | 100 |
| Cagrilintide | Incretin | 3 n=3 | 98.13 | 98.69 | -0.56 | 96.5 | 100 |
| N-Acetyl Semax Amide | Neuroactive | 3 n=3 | 98.57 | 99.35 | -0.78 | 98.5 | 67 |
| 5-Amino-1MQ | Non-peptide | 2 n=2 | n<3 | 99.45 | — | 98.0 | 100 |
| KPV | Tissue-repair | 2 n=2 | n<3 | 99.64 | — | 99.0 | 0 |
| ARA-290 | Tissue-repair | 2 n=2 | n<3 | 99.42 | — | 98.0 | 100 |
| Desmopressin | Hypothalamic | 2 n=2 | n<3 | 98.83 | — | 98.5 | 100 |
| L-Glutathione (reduced) | Short | 1 n=1 | n<3 | 99.33 | — | 98.5 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 0 | 0 | n<3 | — | 0 |
| 2024-Q2 | 1 | 2 | n<3 | 98.07–99.82 | 1 |
| 2024-Q3 | 2 | 10 | 98.13 | 97.83–98.43 | 1 |
| 2024-Q4 | 6 | 37 | 98.80 | 97.55–99.50 | 1 |
| 2025-Q1 | 6 | 44 | 98.50 | 97.74–99.93 | 7 |
| 2025-Q2 | 5 | 29 | 98.89 | 97.63–99.38 | 6 |
| 2025-Q3 | 3 | 25 | 98.37 | 97.45–99.93 | 4 |
| 2025-Q4 | 9 | 30 | 98.80 | 98.02–99.93 | 16 |
| 2026-Q1 | 9 | 42 | 98.72 | 97.34–99.93 | 4 |
| 2026-Q2 | 21 | 138 | 99.02 | 97.37–99.93 | 38 |
| 2026-Q3 | 3 | 14 | 98.90 | 97.70–99.54 | 0 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 172 | 98.71 | +0.00 | 98.71 |
| PeptideMeter | 59 | 98.75 | -0.05 | 98.80 |
| Medutest | 53 | 98.83 | +0.08 | 98.75 |
| VendorInvestigate | 35 | 98.47 | -0.11 | 98.58 |
| Nordanalyt | 31 | 98.87 | +0.02 | 98.85 |
| Kestrel | 21 | 99.28 | +0.24 | 99.04 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
93.0/ 1001,458 ratings across the index network
s.weiss100/100
Twelve orders, every label square, printed and legible, lot code matching the paperwork on each.
k.kravchenko99/100
9 orders, 18 months. No substitution, no reformulation, no post-payment unavailability. Independent verification of individual lots still required.
n.okonkwo98/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. PeptideMeter report held on file, figures match published. Evidence base adequate for a rating on this criterion.
y.bergstrom97/100
Declared figure not adjusted upward between certificate and commercial documentation. Contributor declares no interest beyond the transaction.
h.lundgren96/100
Published stock status matched availability. Same-day dispatch. Record covers the lots named. Not generalised.
ta.kaufmann95/100
Line quoted that three comparable suppliers declined to quote. Material returned within specification. Identity confirmed by two orthogonal methods. Documentation practice, not a single purity figure, is the substance here.
t.malinowski99/100
Storage condition for the stability statement stated on the certificate. Supplementary certificate produced without demur. Independent verification of individual lots still required.
a.lehtinen98/100
Consistency: 9 lots, purity band under 1.0 points wide. Not medical advice.
m.nyberg100/100
Stated storage condition on the certificate matched the shipping condition on the consignment. Reorder within 0.1 points of the original.
r.lokken97/100
Peptide content reported separately from chromatographic purity across all 6 certificates held. n=1, declared as n=1.
s.adeyemi100/100
Quote returned with the right vial size and the price held through to invoice. Material returned 99.0%.
a.castellanos99/100
Cold chain intact. Phase-change pack solid at arrival, day 7. Identity confirmed by two orthogonal methods. Evidence base adequate for a rating on this criterion.
v.nwosu95/100
Repeat determination at 24 months: 98.8%. Original: 98.8%. No drift detected in this sample. Vial-to-vial mass variation under 2%.
h.kravchenko98/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Further submissions on later lots would improve coverage.
m.vermeulen100/100
Phase-change pack hard on arrival. Cake intact, no melt-back, no shift in the vial. Research use. Not approved for human administration.
p.kowalski95/100
Labelling printed, lot and date legible on every unit examined. Freight and documentation quoted separately from material cost, itemised on the invoice as quoted. Subsequent orders placed with the same supplier.
l.rautio96/100
Two lots ordered deliberately for comparison. Reported purities 0.1 points apart. Nothing unsecured in the consignment. Evidence base adequate for a rating on this criterion.
a.wojcik99/100
Cross-check: Medutest and PeptideMeter, same lot, agreement to 0.1 points. Both agree with the declared figure. Contributor declares no interest beyond the transaction.
c.kuipers95/100
Release signed and dated, named individual. Record covers the lots named. Not generalised.
no.zielinski98/100
Retention time assigned to the principal peak, printed. Gradient and column chemistry stated. Research use. Not approved for human administration.
f.grimaldi97/100
Documentation complete at first issue. No supplementary request raised. No further comment.
d.wojcik95/100
Batch record supplied in full on request, attached rather than summarised. Not medical advice.
sa.lindqvist99/100
Custom synthesis delivered 4 days inside the quoted schedule at the specified purity. Figures as reported by the named service. Not reproduced by the index.
l.broberg97/100
Certificate carries counter-ion identity and content. Complete against the index minimum data set at first issue. Identity confirmed by two orthogonal methods.
i.pires96/100
Direct-supply material 97.5%. Intermediary vial, same nominal description, 97.7%. Subsequent orders placed with the same supplier.
Block 12
Most recent records
Block 13
Contributor annotations on GGPeps records 537
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on GGPeps material are below, each linked to the record it sits on.
Detection wavelength does not affect a mass determination but it does affect the purity figure sitting next to it. Both are stated on this record, which is the point.
n=1 on this lot. A single result below specification is a finding about a vial. Two agreeing results would make it a finding about a lot, and the batch page will say which of those exists.
Buyer-sourced through an ordinary retail order, so the supplier had no opportunity to select the vial. This is the provenance class the index weights and it is roughly 87 % of the dataset.
Area percent assumes unit response factors across every species present. At 99.54 % the assumption barely matters — there is not enough impurity for a response-factor error to move the figure by a tenth.
The reported figure derives from the plate count and the retention gap, via the pharmacopoeial form with the sum of both peak widths in the denominator. It is a calculated quantity, not a measured one, and it inherits the plate count's uncertainty.
The isotope pattern is consistent with the elemental composition of CJC-1295 (no DAC). That is a second, independent check on identity and it agrees with the mass.
A data logger in the box would upgrade this record further. Custody is documented; temperature history is inferred, and inference is weaker than measurement.
99.43 % on Melanotan II sits at the top of what this index sees. Read it with the method: Medutest ran a 25 min gradient here, and the compound fingerprint names a mass-identical species that a shorter run folds into the main peak. On this gradient the figure is well founded.
Every annotation the index holds on GGPeps material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what GGPeps itself publishes, open ggpeps.net → alongside.
Block 14
Where to buy GGPeps
Nantong Guangyuan Chemical Co., Ltd. sells direct from ggpeps.net. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the GGPeps store at ggpeps.net →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.